Celmatix is a preclinical-stage biotech transforming ovarian health. The lead indication for our ovarian senescence program, currently in preclinical development, is chemotherapy-induced ovarian failure. We have also partnered programs and collaborations focused on polycystic ovary syndrome (PCOS) and contraception supported by our multi-omics platform.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2009
Main Therapeutic Focus:
Reproductive/Sexual Health
Lead Product in Development:
Chemotherapy-Induced Ovarian Failure
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
